Heatwurx Inc. (NASDAQ:PCSA) Short Interest Down 65.4% in February

Heatwurx Inc. (NASDAQ:PCSA) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 10,356 shares, a decline of 65.4% from the January 29th total of 29,972 shares. Based on an average trading volume of 66,959 shares, the short-interest ratio is currently 0.2 days. Approximately 0.5% of the company’s shares are short sold. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 66,959 shares, the short-interest ratio is currently 0.2 days.

Heatwurx Price Performance

Shares of NASDAQ:PCSA traded down $0.06 during trading on Friday, hitting $2.17. The company’s stock had a trading volume of 8,075 shares, compared to its average volume of 67,312. The company has a 50-day moving average of $2.90 and a 200-day moving average of $5.27. The firm has a market cap of $4.93 million, a price-to-earnings ratio of -0.06 and a beta of 1.14. Heatwurx has a 12 month low of $1.76 and a 12 month high of $19.64.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen cut Heatwurx from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $25.00.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.